Pfizer Drops Immune Response's HIV Drug

Take-Two affirms guidance; IBM down after Goldman cuts estimates; and more stocks in the news

Immune Response (IMNR ) says Pfizer's Agouron Pharma unit has terminated further development of Remune, the company's investigational HIV drug. Immune Response shares were trading sharply lower.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.